Researchers in Germany recently evaluated executive functions in 36 patients who were diagnosed with PKU during childhood. Significant negative correlations were observed between elevated childhood ...
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
- Conference call and webcast to be held at 8:00 AM EDT - SOUTH PLAINFIELD, N.J., May 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was ...
Credit: Getty Images. The investigational therapy is an oral formulation of synthetic sepiapterin. Sepiapterin significantly reduced blood phenylalanine levels in adult and pediatric patients with ...
DEER PARK, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases ...
The new study enrolled 16 healthy males, who participated in 2 trials: treadmill exercise followed by a PKU-type meal or an hour of rest prior to the same meal. After exercise, changes in postprandial ...
When Joni Arneson goes out to eat, she's not likely to order a steak. For one thing, she doesn't like meat. But more importantly, an overload of protein could give her a severe headache. Arneson is a ...
Paolo Galfetti, chief operating officer of Relief Therapeutics and chief executive officer of APR Applied Pharma Research SA, shares his family's rare story of living with phenylketonuria GENEVA, ...
On Friday, the U.S. Food and Drug Administration (FDA) approved BioMarin Pharmaceutical Inc.’s supplemental application for Palynziq (pegvaliase-pqpz), a treatment for phenylketonuria (PKU) in ...
Otsuka Pharmaceutical is broadening its scope in rare disease, striking a deal to acquire Jnana Therapeutics and its lead drug candidate, a small molecule on track for pivotal testing in a metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results